Does allopurinol (a xanthine oxidase inhibitor) have clinically useful anti-ischaemic effects in angina pectoris? - A randomised, double-blind, placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-004611-21-GB

Enrollment

Unknown

Registered

2006-11-22

Start date

2008-12-29

Completion date

Unknown

Last updated

2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina Pectoris MedDRA version: 8.1 Level: LLT Classification code 10002383 Term: Angina pectoris

Interventions

Trade Name: Allopurinol Pharmaceutical Form: Tablet INN or Proposed INN: ALLOPURINOL CAS Number: 315300 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 300-600 Phar

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who fulfill all of the followings: 1) age between 30 and 85 years 2) documented coronary artery disease on coronary angiography 3) angina pectoris for > 2 months 4) stable anti-anginal therapy for > 1 month 5) 2 positive exercise treadmill tests for ischaemia, done within a 2 week period and the time to ST depression on the second exercise test must be within 15% of the first test Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients will be excluded if they: 1) do not fulfill any of the inclusion criteria 2) have heart failure or left ventricular systolic dysfunction (LV ejection fraction 180) 6) have gout and already on allopurinol

Design outcomes

Primary

Measure	Time frame
Main Objective: The main objective is to investigate if allopurinol (a xanthine oxidase inhibitor) has a clinically useful anti-ischaemic effects in patients with angina pectoris. This will primarily be assessed by the exercise treadmill test using a standard full Bruce protocoal. Patients will also be asked to record the number of angina attacks per week and their GTN consumption. ;Secondary Objective: ;Primary end point(s): This will be assessed using exercise treadmill test with the primary outcome measure being the time to 0.1mv ST depression.	—

Measure

Time frame

Main Objective: The main objective is to investigate if allopurinol (a xanthine oxidase inhibitor) has a clinically useful anti-ischaemic effects in patients with angina pectoris. This will primarily be assessed by the exercise treadmill test using a standard full Bruce protocoal. Patients will also be asked to record the number of angina attacks per week and their GTN consumption. ;Secondary Objective: ;Primary end point(s): This will be assessed using exercise treadmill test with the primary outcome measure being the time to 0.1mv ST depression.

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026